Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Sep;5(3):217-27.
doi: 10.1007/s11523-010-0151-8. Epub 2010 Aug 25.

Immune therapeutic targeting of glioma cancer stem cells

Mustafa Aziz Hatiboglu  1 , Jun Wei, Adam Sauh Gee Wu, Amy B Heimberger
Affiliations
Review

Immune therapeutic targeting of glioma cancer stem cells

Mustafa Aziz Hatiboglu et al. Target Oncol. 2010 Sep.

Abstract

Glioblastoma multiforme (GBM) is a lethal cancer that responds poorly to radiotherapy and chemotherapy. Glioma cancer stem cells (gCSCs) have been shown to recapitulate the characteristic features of GBM and to mediate chemotherapy and radiation resistance. Immunotherapeutic targeting of this cell population holds therapeutic promise but must be considered in the context of the immunosuppressive properties mediated by the gCSC. Recent findings have indicated that this goal will be challenging because the gCSC can suppress both the innate and adaptive immune systems by a variety of gCSC-secreted products and cell-membrane interactions. In this review article, we will attempt to reconcile the disparate research findings regarding the potential of immune targeting of the gCSC and propose several novel solutions.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. The degree of gCSC mediated immune suppression associates with in vivo tumorigenicity but not with CD133 expression
The gCSCs (2 × 106) were cultured in neural stem cell medium for 5 days, and then the supernatant medium was harvested for testing immunosuppressive properties. Additionally, the gCSCs (5 × 104) were intracranially implanted in nude mice (6 per group). A. The percentage of inhibited T-cell proliferation does not correlate with gCSC CD133 expression levels. B. The number of induced Foxp3+ Tregs does not correlate with the gCSC CD133 expression levels. C. Increased T-cell apoptosis does not correlate with gCSC CD133 expression levels. D. The amount of gCSC-produced galectin-3 associates with CD133 expression. E. The percentage of inhibited T-cell proliferation inversely associates with the mean survival time of gCSC-implanted animals. F. The number of induced Foxp3+ Tregs inversely associates with the mean survival time of gCSC-implanted mice. G. Increased T-cell apoptosis inversely associates with the mean survival time of gCSC-implanted animals. H. The gCSC CD133 expression levels do not correlate with the mean survival of gCSC-implanted animals.
Fig. 2
Fig. 2. Theoretical schema showing relationship between glioma cancer stem cells and the immune system
The gCSCs express p-STAT3, which in addition to inducing gCSC proliferation and self-renewal, is also capable of inducing p-STAT3 expression in a wide variety of immune cell populations via a feed forward mechanism. This up regulation of p-STAT-3 in the immune cells down modulates effector function such as T-cell activation, proliferation, and elaboration of effector cytokine production. The gCSC secretes a variety of factors: macrophage inhibitory cytokine, which inhibits macrophage phagocytosis; transforming growth factor (TGF-β1), which induces Tregs and polarizes the macrophage to an immunosuppressive M2 state; soluble colony stimulating factor (sCSF-1), which recruits circulating monocytes and also mediates differentiation and polarization of the monocyte into M2 tumor-associated macrophages; chemokine (C-C motif) ligand 2 (CCL-2), which enhances Treg tumor infiltration; and galectin-3, which triggers T-cell apoptosis. Additionally, the cell-surface expression of the costimulatory inhibitory molecule B7-H1, which mediates immune suppression by a variety of mechanisms, and the down modulation of the major histocompatibility complex (MHC) further enhance the immunosuppressive properties of the gCSCs.
Fig. 3
Fig. 3. Decrease in immunosuppressive properties in gCSCs maintained in vitro over many passages
Comparison of early and late passage gCSCs (n = 4) showing decrease with later passages in (A) the production of TGF-β1 (p = 0.10), and sCSF-1 (p = 0.05), (B) the ability to induce macrophages (MΦ) to secrete the immunosuppressive cytokines IL-10 (p = 0.05) and IL-23 (n = 2, p = 0.05), and (C) the ability to inhibit T-cell proliferation (p = 0.008). Late passages were 15-20 passages after early passages. P-values calculated using student’s t-test.
See this image and copyright information in PMC

References

    1. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253–1261. - PubMed
    1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–3988. - PMC - PubMed
    1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–737. - PubMed
    1. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–10951. - PubMed
    1. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA. 2003;100:15178–15183. - PMC - PubMed

Publication types

Substances